A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis

Abstract

Abstract Targeting the metastatic process is a critical pursuit in the treatment of malignant disease. There are currently no specific anti‐metastatic drugs approved for clinical use, despite metastasis being the leading cause of death for cancer patients. Targeting the Tie1 receptor was shown as a possible strategy for selective anti‐metastasis therapies based on previous gene deletion studies. This current study is the first description of a human antibody against Tie1 with the potential for clinical use in targeting extravasation of tumor cells into organs such as the lung, without having a detrimental effect on immune cell infiltration.